ProCE Banner Activity

CE / CME

Expert Perspectives on Integrating Immuno-Oncology Therapeutics Into the Management of Metastatic Triple-Negative Breast Cancer

Text Module
Review the latest developments in immuno-oncology strategies for managing metastatic TNBC with this set of expert commentaries, including optimal use of immune checkpoint inhibition, management of immune-related toxicities, and future directions.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: May 14, 2020

Expiration: May 13, 2021

No longer available for credit.

Share

Faculty

Sarah Donahue

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

David B. Page

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

Hope S. Rugo

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Peter Schmid

Peter Schmid, MD, PhD, FRCP

Centre Lead
Centre of Experimental Cancer Medicines
Barts Cancer Institute
Clinical Director
St Bartholomew Breast Cancer Centre
Barts Hospital
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with metastatic triple-negative breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify patients with metastatic triple-negative breast cancer who are most likely to benefit from immune checkpoint inhibitors as single agents or in combination with chemotherapy
  • Plan first-line treatment with immune checkpoint inhibitors as single agents or in combination with chemotherapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations on immune checkpoint inhibitors for patients with progressive triple-negative breast cancer after one or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune checkpoint inhibitors in patients with breast cancer
  • Recommend ongoing clinical trials assessing single-agent and/or combination immunotherapy approaches for appropriate patients with breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Sarah Donahue, MPH, NP, has no relevant conflicts of interest to report.

David B. Page, MD

Assistant Member, Medical Oncology
Medical Oncologist
Providence Cancer Institute
Providence Health & Services
Portland, Oregon

David B. Page, MD, has disclosed that he has received consulting fees from Brooklyn ImmunoTherapeutics and Genentech; funds for research support from Bristol-Myers Squibb, Brooklyn ImmunoTherapeutics, and Merck; and fees for non-CME/CE services from Genentech and Novartis.

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Hope S. Rugo, MD, has disclosed that she has received funds for research support from Daiichi, Eisai, Genentech, Immunomedics, Lilly, MacroGenics, Merck, Novartis, OBI, Odonate, Pfizer, and Seattle Genetics; has received consulting fees from Ionis and Celltrion; and has received support for travel from Amgen, AstraZeneca, Daiichi, MacroGenics, Merck, Pfizer, and Puma.

Peter Schmid, MD, PhD, FRCP

Centre Lead
Centre of Experimental Cancer Medicines
Barts Cancer Institute
Clinical Director
St Bartholomew Breast Cancer Centre
Barts Hospital
London, United Kingdom

Peter Schmid, MD, PhD, FRCP, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Puma, and Roche and funds for research support paid to his institution from Genentech, Novartis, OncoGenex, and Roche and that his spouse has received consulting fees from Genentech and Roche.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael Andrie, PhD, has no relevant conflicts of interest to report.

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-058-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 14, 2020, through May 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with metastatic triple-negative breast cancer.